Cytosorbents (CTSO) Q2 2026 Earnings Report

The call presented a balanced mix of operational progress and material challenges. Positives include stable revenue (~$9.6M), improved gross margin (73%), reduced operating loss (down ~27%), meaningful adjusted metric improvements (adjusted EBITDA loss down ~38%), lower cash burn (net operating burn ~ $200k excluding restructuring) and encouraging safety/efficacy signals and regulatory engagement for DrugSorb-ATR (publication, safety profile, significant subset results and a defined FDA path). Offsetting these are the missed primary efficacy endpoint in the mITT population, the FDA's prior de novo denial (appeal upheld) requiring additional mechanistic and RWE data, protocol imbalances in STAR-T that complicate interpretation, market headwinds in Germany and the Middle East, a modest cash balance (~$5.9M) and continued net losses. Given the meaningful operational and clinical positives tempered by substantive regulatory, clinical robustness and funding risks, the overall tone is balanced.

Management guided that it expects to achieve operating cash‑flow breakeven in the second half of 2026, supported by Q2 results of ~$9.6M revenue (up 9% sequentially), 73% gross margin (vs 69% in Q1), a 27% reduction in operating loss to $2.6M, a 38% improvement in adjusted EBITDA loss to $1.6M, an adjusted net loss improvement of 22% to $2.9M ($0.05/sh), and materially lower cash burn (Q2 cash burn $400k including ~$200k restructuring, or ~ $200k net operating burn), with total cash of ~$5.9M at 6/30/26; operational actions include adding 3–5 sales reps through early‑2027 and continuing distributor expansion (distributor territories +16% YoY, direct sales outside Germany +9% YoY) to drive growth. For DrugSorb‑ATR the company reiterated plans to pursue a new de‑novo submission (after pre‑submission meetings later this month) using additional mechanistic data plus real‑world evidence rather than a new pivotal trial, citing STAR‑T trial toplines (140 randomized, mITT 132, CABG per‑protocol 111; win ratio 1.59 for severe bleeding, 58% relative risk reduction / 16.3% absolute reduction, NNT=6) and two FDA Breakthrough designations; HemoDefend‑BGA progress (>$16M non‑dilutive DoD funding, 15‑minute cartridge processing, >1 year shelf life) was also highlighted as a near‑term strategic value driver over the next 6–18 months.